scholarly article | Q13442814 |
P50 | author | Alessandro Biffi | Q91821855 |
Patrick T Ellinor | Q57775928 | ||
David M. Greer | Q64136824 | ||
P2093 | author name string | Natalia S Rost | |
Karen L Furie | |||
Lisa Cloonan | |||
Peter Kelly | |||
John Chorba | |||
P2860 | cites work | Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment | Q22306370 |
Predicting outcome in ischemic stroke: external validation of predictive risk models | Q30310381 | ||
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association | Q30434464 | ||
Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank | Q30664833 | ||
Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). | Q33377421 | ||
Mortality and predictors of death 1 month and 3 years after first-ever ischemic stroke: data from the first national acute stroke Israeli survey (NASIS 2004). | Q33518989 | ||
Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study | Q33697952 | ||
Gender differences in outcomes after ischemic stroke: role of ischemic lesion volume and intracranial large-artery occlusion | Q34354508 | ||
Predicting functional outcome and survival after acute ischemic stroke | Q34761089 | ||
Long-Term Outcome after Ischaemic Stroke/Transient Ischaemic Attack | Q35108042 | ||
Race and gender differences in 1-year outcomes for community-dwelling stroke survivors with family caregivers | Q35114083 | ||
Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community | Q35575045 | ||
B-type natriuretic peptide: issues for the intensivist and pulmonologist | Q36251643 | ||
Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke | Q37208520 | ||
State of the art: using natriuretic peptide levels in clinical practice | Q37257460 | ||
N-terminal probrain natriuretic peptide predicts 1-year mortality following acute stroke: possible evidence of occult cardiac dysfunction among patients with acute stroke | Q85040496 | ||
Blood markers for the prognosis of ischemic stroke: a systematic review | Q37415033 | ||
Time to treatment and acute coronary syndromes: bridging the gap in rapid decision making. | Q37779238 | ||
Thromboembolic complications in atrial fibrillation | Q38140438 | ||
Factors affecting the B-type natriuretic peptide levels in stroke patients | Q43036265 | ||
Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. | Q43529232 | ||
Three-month stroke outcome: the European Registers of Stroke (EROS) investigators | Q43988905 | ||
Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death | Q44279052 | ||
Inflammation, homocysteine, and vitamin B6 status after ischemic stroke | Q44681253 | ||
Predicting outcome after acute ischemic stroke: an external validation of prognostic models | Q47189349 | ||
Comparison of clinical characteristics and functional outcomes of ischemic stroke in different vascular territories. | Q48113272 | ||
Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time | Q48126208 | ||
Plasma brain natriuretic peptide predicts death during hospitalization in acute ischaemic stroke and transient ischaemic attack patients with atrial fibrillation | Q48174572 | ||
Rate, degree, and predictors of recovery from disability following ischemic stroke | Q48176169 | ||
The real estate factor: quantifying the impact of infarct location on stroke severity | Q48360959 | ||
Atrial fibrillation after acute stroke | Q48365357 | ||
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke | Q48389128 | ||
Influence of stroke survivor characteristics and family conflict surrounding recovery on caregivers' mental and physical health | Q48509999 | ||
B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department | Q48701295 | ||
A three-item scale for the early prediction of stroke recovery. | Q48819164 | ||
Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation | Q48921662 | ||
Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association | Q48948869 | ||
Auckland Stroke Outcomes Study. Part 1: Gender, stroke types, ethnicity, and functional outcomes 5 years poststroke. | Q48971062 | ||
A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. | Q51905089 | ||
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations | Q73736775 | ||
NT-pro-BNP is associated with long-term outcome in a heterogeneous sample of cardiac inpatients | Q80194349 | ||
Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis | Q81158100 | ||
Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation | Q81223583 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | brain natriuretic peptide | Q66360952 |
P304 | page(s) | 441-445 | |
P577 | publication date | 2011-11-23 | |
P1433 | published in | Stroke Journal | Q7624282 |
P1476 | title | Brain natriuretic peptide predicts functional outcome in ischemic stroke | |
P478 | volume | 43 |
Q48552186 | Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity. |
Q36642014 | Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy |
Q44304248 | Aortic stiffness and plasma brain natriuretic peptide predicts mortality in acute ischemic stroke |
Q55100653 | Associated Factors with Left Atrial Enlargement in Patients with Acute Ischemic Stroke. |
Q40347969 | Association Between Subclinical Cardiac Biomarkers and Clinically Manifest Cardiac Diseases With Cortical Cerebral Microinfarcts |
Q26861828 | B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis |
Q33967122 | BNP but Not s-cTnln is associated with cardioembolic aetiology and predicts short and long term prognosis after cerebrovascular events |
Q27004404 | Biomarkers for stroke |
Q95492624 | Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation |
Q48360592 | Brain natriuretic peptide is associated with worsening and mortality in acute stroke patients but adds no prognostic value to clinical predictors of outcome. |
Q92126943 | Brain-heart interaction after acute ischemic stroke |
Q37273542 | C-reactive protein and B-type natriuretic peptide yield either a non-significant or a modest incremental value to traditional risk factors in predicting long-term overall mortality in older adults |
Q33715302 | Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk |
Q38188010 | Cardioembolic stroke diagnosis using blood biomarkers |
Q35193631 | Difference in the prognostic significance of N-terminal pro-B-type natriuretic peptide between cardioembolic and noncardioembolic ischemic strokes |
Q89820429 | Dynamic Changes and Prognostic Value of Gut Microbiota-Dependent Trimethylamine-N-Oxide in Acute Ischemic Stroke |
Q36152775 | Markers of cardiac dysfunction in cognitive impairment and dementia |
Q36383798 | N-terminal pro-brain natriuretic peptide levels and short term prognosis in acute ischemic stroke |
Q38270771 | Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles. |
Q41921395 | Opinions about the use of brain natriuretic peptide among acute ischemic stroke patients |
Q41485181 | Quality of life predictors in chronic stable post-stroke patients and prognostic value of SF-36 score as a mortality surrogate |
Q36607714 | Risk factors for pulmonary hypertension in patients receiving maintenance peritoneal dialysis |
Q92346175 | Serum B-type natriuretic peptide level and timing of its measurement as a predictor of acute ischemic stroke outcome |
Q47733196 | Serum N-terminal proBNP, not troponin I, at presentation predicts long-term neurologic outcome in acute charcoal-burning carbon monoxide intoxication. |
Q41357862 | Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke |
Q64093570 | Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke |
Q26849846 | Stroke rehabilitation: recent advances and future therapies |
Q48695759 | Stroke: Brain natriuretic peptide could be a biomarker for outcomes after cardioembolic stroke |
Q36733964 | Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study |
Search more.